GlassScriptPhysician profile
Luis E Zayas-Rodriguez
NPI 1184823312
$6,152.66
in general payments reported to CMS, 2019-2025
22 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2021: $810 · 2022: $1,378 · 2023: $1,831 · 2024: $574 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965 · Travel and Lodging: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.66 |
| Travel and Lodging | $938.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,753.49 | 2019-2021 | |
| Medtronic, INC. | $1,404.74 | 2022-2023 | Percept PC Brainsense, Sensight |
| Acadia Pharmaceuticals INC | $1,171.15 | 2022-2025 | Nuplazid |
| Abbvie INC. | $414.08 | 2022-2025 | Duopa, Botox |
| Neurocrine Biosciences, INC. | $213.95 | 2021-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $183.39 | 2021-2025 | Rytary, Crexont |
| Teva Pharmaceuticals USA, INC. | $156.15 | 2021-2024 | Austedo Xr, Austedo |
| Revance Therapeutics, INC. | $143.26 | 2024 | Daxxify |
| Kyowa Kirin, INC. | $128.30 | 2021-2024 | Nourianz |
| Mdd US Operations, LLC | $114.20 | 2023-2025 | Apokyn, Gocovri |
| Ucb, INC. | $92.41 | 2022-2025 | Briviact |
| Merz Pharmaceuticals, LLC | $89.98 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Biogen, INC. | $65.58 | 2023-2024 | Skyclarys, Skyclarys |
| Ipsen Biopharmaceuticals, INC | $38.65 | 2024-2025 | Dysport |
| Acorda Therapeutics, INC | $38.54 | 2022-2024 | Inbrija |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $31.79 | 2021 | |
| Jazz Pharmaceuticals INC. | $28.07 | 2025 | |
| Pfizer INC. | $20.30 | 2025 | |
| Avion Pharmaceuticals | $17.29 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.14 | 2022 | |
| C2n Diagnostics, LLC | $16.20 | 2025 | Precivityad2 |
| Abbott Laboratories | $14.00 | 2025 | Infinity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Zayas-Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.